MotivaChew™ Executive Summary
Postoperative ileus (POI) is a frequent and costly complication of abdominal and pelvic surgery, leading to delayed gastrointestinal motility, patient discomfort, prolonged hospitalization, and elevated healthcare costs. While Enhanced Recovery After Surgery (ERAS) protocols have improved outcomes, there is no optimized, non-pharmaceutical intervention specifically designed to stimulate gastrointestinal recovery.MotivaChew™ is an innovative, patent-pending bioactive chewing gum formulated to stimulate vagal nerve activity and enhance gastrointestinal motility postoperatively. Importantly, MotivaChew™ also targets opioid-induced contributors to POI, addressing a key mechanism of delayed recovery through a unique combination of mechanical stimulation and GRAS-certified bioactive ingredients.Phase I Goals:
- Optimize the MotivaChew™ formulation
- Conduct stability, release, and sensory testing
- Perform a pilot usability and tolerability study in post-surgical patientsInnovation & Commercialization Potential:
MotivaChew™ is the first chewing gum specifically optimized for clinical use in ERAS pathways, offering a novel, scalable adjunct to surgical recovery care. It addresses a large, growing market (~5 million surgeries annually in the US) and aligns with NIDDK’s mission to improve gastrointestinal health.For additional information, please contact:
Gregory P. Bobbitt
Founder & Principal Investigator
MotivaHealth LLC
Email: [email protected]
MotivaChew™ Pitch Deck
The Problem
Postoperative ileus delays bowel function and increases costs
• Affects up to 30% of abdominal surgeries
• Average extra hospital cost: $10–20K per patient
• Prolonged pain, opioid use, and patient dissatisfactionOur Solution
Bioactive chewing gum that stimulates GI motility
• Combines mastication with GRAS functional ingredients
• Drug‑free, non‑invasive, patient‑preferred
• Targets bowel function and reduces opioid relianceTechnology & IP
Two patents filed:
1. Functional formulation for GI motility
2. Opioid‑related gut dysfunction approach
• Time‑release micro‑encapsulation
• Protects key ingredient ratios and delivery methodMarket Opportunity
U.S. addressable market:
• 7M+ abdominal surgeries annually
• $2.5B potential spend on ERAS GI solutions
Initial beachheads: colorectal, gynecological, C‑sectionTraction & Partners
Key milestones achieved:
• Collaborations: FRL and University of Wisconsin
• SAM.gov, Grants.gov, Research.gov, SBIR.gov active
• NSF SBIR Project Pitch accepted and ready for Phase 1 ProposalBusiness Model & Go To Market
Phase 1 – Hospital & Surgical Centers
• Bundled sales with ERAS kits
• Reimbursement via hospital supply budgets
Phase 2 – OTC / Home Recovery
• Retail pharmacies & e‑commerce
Phase 3 – Licensing to pharma/device partnersMilestones & Road Map
Next 18 months:
• Finalize formulation & stability studies (Q3 2025)
• Pilot clinical study – 60 patients (Q1 2026)
• Submit Phase I NSF SBIR (Q4 2025)
• FDA regulatory pathway planning (ongoing)Financial & Investment Ask
Seed Round – $250K Convertible Note
• Valuation cap: $1M
• 20% discount at conversion
• 5% interest, 18‑month term
Use of funds: R&D, clinical pilot, regulatory prepOur Team
Gregory Bobbitt – Founder & CEO
• Entrepreneur & author with patient‑centered care focus
Advisors:
- Surgical Oncologist
- Gastroenterologist
- Pharmacology expertThank You
Questions? Let’s talk.
Gregory Bobbitt – [email protected](704) 654‑5078
Our Mission
Our mission is guided by compassion, clinical insight, and a relentless commitment to making recovery more humane, and more effective. From concept to patent to pilot testing, we're building MotivaChew™ with integrity, evidence, and people in mind.
Contact Us
Gregory Bobbitt
Founder, MotivaChew™